JMP Securities initiated coverage of Pardes Biosciences (NASDAQ:PRDS) with a “market outperform” rating and price target of $9. The stock closed at $1.15 on Dec. 12. Pardes is developing PBI-0451 as a potential novel...
SVB Leerink launched coverage of Pardes Biosciences (NASDAQ:PRDS) with an “outperform” rating and $18 price target. The stock closed at $5.54 on March 14. Pardes is a clinical-stage biopharmaceutical company created to...